These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22266126)

  • 1. Treatment of psoriasis with interleukin-12/23 monoclonal antibody: a systematic review.
    Wu Y; Chen J; Li YH; Ma GZ; Chen JZ; Gao XH; Chen HD
    Eur J Dermatol; 2012; 22(1):72-82. PubMed ID: 22266126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ustekinumab.
    Weber J; Keam SJ
    BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
    Farhi D
    Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease.
    Shear NH; Prinz J; Papp K; Langley RG; Gulliver WP
    J Cutan Med Surg; 2008 Dec; 12 Suppl 1():S1-10. PubMed ID: 19886505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
    Gottlieb AB; Cooper KD; McCormick TS; Toichi E; Everitt DE; Frederick B; Zhu Y; Pendley CE; Graham MA; Mascelli MA
    Curr Med Res Opin; 2007 May; 23(5):1081-92. PubMed ID: 17519075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
    Kurzeja M; Rudnicka L; Olszewska M
    Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab for the treatment of psoriasis.
    Laws PM; Warren RB
    Expert Rev Clin Immunol; 2011 Mar; 7(2):155-64. PubMed ID: 21426253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
    Tan JY; Li S; Yang K; Ma B; Chen W; Zha C; Zhang J
    J Dermatolog Treat; 2011 Dec; 22(6):323-36. PubMed ID: 20923370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biologic therapies in development targeting IL-12/IL-23.
    van de Kerkhof PC
    J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():5-9. PubMed ID: 20831703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV; Exter BP; Steinberg M; Jarvis CI
    Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
    Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
    Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
    Zaghi D; Krueger GG; Callis Duffin K
    J Drugs Dermatol; 2012 Feb; 11(2):160-7. PubMed ID: 22270196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
    Krueger GG; Langley RG; Leonardi C; Yeilding N; Guzzo C; Wang Y; Dooley LT; Lebwohl M;
    N Engl J Med; 2007 Feb; 356(6):580-92. PubMed ID: 17287478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
    Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
    Krueger JG; Ferris LK; Menter A; Wagner F; White A; Visvanathan S; Lalovic B; Aslanyan S; Wang EE; Hall D; Solinger A; Padula S; Scholl P
    J Allergy Clin Immunol; 2015 Jul; 136(1):116-124.e7. PubMed ID: 25769911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases.
    Wittig BM
    Curr Opin Investig Drugs; 2007 Nov; 8(11):947-54. PubMed ID: 17979029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.